126 related articles for article (PubMed ID: 22960695)
1. Ligand-based designing, in silico screening, and biological evaluation of new potent fructose-1,6-bisphosphatase (FBPase) inhibitors.
Tayyem RF; Zalloum HM; Elmaghrabi MR; Yousef AM; Mubarak MS
Eur J Med Chem; 2012 Oct; 56():70-95. PubMed ID: 22960695
[TBL] [Abstract][Full Text] [Related]
2. Design, synthesis and biological evaluation of 7-nitro-1H-indole-2-carboxylic acid derivatives as allosteric inhibitors of fructose-1,6-bisphosphatase.
Bie J; Liu S; Zhou J; Xu B; Shen Z
Bioorg Med Chem; 2014 Mar; 22(6):1850-62. PubMed ID: 24530031
[TBL] [Abstract][Full Text] [Related]
3. Elaborate ligand-based modeling and subsequent synthetic exploration unveil new nanomolar Ca2+/calmodulin-dependent protein kinase II inhibitory leads.
Shahin R; Taha MO
Bioorg Med Chem; 2012 Jan; 20(1):377-400. PubMed ID: 22112539
[TBL] [Abstract][Full Text] [Related]
4. Discovery of novel indole derivatives as allosteric inhibitors of fructose-1,6-bisphosphatase.
Bie J; Liu S; Li Z; Mu Y; Xu B; Shen Z
Eur J Med Chem; 2015 Jan; 90():394-405. PubMed ID: 25461330
[TBL] [Abstract][Full Text] [Related]
5. Combining ligand-based pharmacophore modeling, quantitative structure-activity relationship analysis and in silico screening for the discovery of new potent hormone sensitive lipase inhibitors.
Taha MO; Dahabiyeh LA; Bustanji Y; Zalloum H; Saleh S
J Med Chem; 2008 Oct; 51(20):6478-94. PubMed ID: 18808096
[TBL] [Abstract][Full Text] [Related]
6. Extensive ligand-based modeling and in silico screening reveal nanomolar inducible nitric oxide synthase (iNOS) inhibitors.
Suaifan GA; Shehadehh M; Al-Ijel H; Taha MO
J Mol Graph Model; 2012 Jul; 37():1-26. PubMed ID: 22609742
[TBL] [Abstract][Full Text] [Related]
7. Elaborate ligand-based modeling reveals new nanomolar heat shock protein 90α inhibitors.
Al-Sha'er MA; Taha MO
J Chem Inf Model; 2010 Sep; 50(9):1706-23. PubMed ID: 20831219
[TBL] [Abstract][Full Text] [Related]
8. Fructose-1,6-bisphosphatase Inhibitors. 2. Design, synthesis, and structure-activity relationship of a series of phosphonic acid containing benzimidazoles that function as 5'-adenosinemonophosphate (AMP) mimics.
Dang Q; Kasibhatla SR; Xiao W; Liu Y; Dare J; Taplin F; Reddy KR; Scarlato GR; Gibson T; van Poelje PD; Potter SC; Erion MD
J Med Chem; 2010 Jan; 53(1):441-51. PubMed ID: 20055427
[TBL] [Abstract][Full Text] [Related]
9. Structure-guided design of AMP mimics that inhibit fructose-1,6-bisphosphatase with high affinity and specificity.
Erion MD; Dang Q; Reddy MR; Kasibhatla SR; Huang J; Lipscomb WN; van Poelje PD
J Am Chem Soc; 2007 Dec; 129(50):15480-90. PubMed ID: 18041833
[TBL] [Abstract][Full Text] [Related]
10. Protein-based alignment in 3D-QSAR of FBPase inhibitors.
Yi P; Di YT; Liu W; Hao XJ; Ming Y; Huang DS; Yang J; Yi ZZ; Li ZJ; Yang RD; Zhang JC
Eur J Med Chem; 2011 Mar; 46(3):885-92. PubMed ID: 21269737
[TBL] [Abstract][Full Text] [Related]
11. In silico screening of a novel scaffold for fructose-1,6-bisphosatase (FBPase) inhibitors.
Huang Y; Chi B; Xu Y; Song R; Wei L; Rao L; Feng L; Ren Y; Wan J
J Mol Graph Model; 2019 Jan; 86():142-148. PubMed ID: 30366190
[TBL] [Abstract][Full Text] [Related]
12. Discovery of potent and specific fructose-1,6-bisphosphatase inhibitors and a series of orally-bioavailable phosphoramidase-sensitive prodrugs for the treatment of type 2 diabetes.
Dang Q; Kasibhatla SR; Reddy KR; Jiang T; Reddy MR; Potter SC; Fujitaki JM; van Poelje PD; Huang J; Lipscomb WN; Erion MD
J Am Chem Soc; 2007 Dec; 129(50):15491-502. PubMed ID: 18041834
[TBL] [Abstract][Full Text] [Related]
13. Synthesis and structure-activity relationship of non-phosphorus-based fructose-1,6-bisphosphatase inhibitors: 2,5-Diphenyl-1,3,4-oxadiazoles.
Liao BR; He HB; Yang LL; Gao LX; Chang L; Tang J; Li JY; Li J; Yang F
Eur J Med Chem; 2014 Aug; 83():15-25. PubMed ID: 24946215
[TBL] [Abstract][Full Text] [Related]
14. Discovery of new nanomolar peroxisome proliferator-activated receptor γ activators via elaborate ligand-based modeling.
Al-Najjar BO; Wahab HA; Tengku Muhammad TS; Shu-Chien AC; Ahmad Noruddin NA; Taha MO
Eur J Med Chem; 2011 Jun; 46(6):2513-29. PubMed ID: 21482446
[TBL] [Abstract][Full Text] [Related]
15. Structure-based design and synthesis of novel dual-target inhibitors against cyanobacterial fructose-1,6-bisphosphate aldolase and fructose-1,6-bisphosphatase.
Li D; Han X; Tu Q; Feng L; Wu D; Sun Y; Chen H; Li Y; Ren Y; Wan J
J Agric Food Chem; 2013 Aug; 61(31):7453-61. PubMed ID: 23889687
[TBL] [Abstract][Full Text] [Related]
16. Synthesis, SAR, and X-ray structure of tricyclic compounds as potent FBPase inhibitors.
Tsukada T; Takahashi M; Takemoto T; Kanno O; Yamane T; Kawamura S; Nishi T
Bioorg Med Chem Lett; 2009 Oct; 19(20):5909-12. PubMed ID: 19762234
[TBL] [Abstract][Full Text] [Related]
17. Design of fructose-2,6-bisphosphatase inhibitors: a novel virtual screening approach.
Shaikh MS; Mittal A; Bharatam PV
J Mol Graph Model; 2008 Feb; 26(6):900-6. PubMed ID: 17644015
[TBL] [Abstract][Full Text] [Related]
18. Orally active aminopyridines as inhibitors of tetrameric fructose-1,6-bisphosphatase.
Hebeisen P; Haap W; Kuhn B; Mohr P; Wessel HP; Zutter U; Kirchner S; Ruf A; Benz J; Joseph C; Alvarez-Sánchez R; Gubler M; Schott B; Benardeau A; Tozzo E; Kitas E
Bioorg Med Chem Lett; 2011 Jun; 21(11):3237-42. PubMed ID: 21550236
[TBL] [Abstract][Full Text] [Related]
19. Discovery of novel allosteric site and covalent inhibitors of FBPase with potent hypoglycemic effects.
Huang Y; Wei L; Han X; Chen H; Ren Y; Xu Y; Song R; Rao L; Su C; Peng C; Feng L; Wan J
Eur J Med Chem; 2019 Dec; 184():111749. PubMed ID: 31589992
[TBL] [Abstract][Full Text] [Related]
20. Fructose-1,6-bisphosphatase inhibitors. 1. Purine phosphonic acids as novel AMP mimics.
Dang Q; Brown BS; Liu Y; Rydzewski RM; Robinson ED; van Poelje PD; Reddy MR; Erion MD
J Med Chem; 2009 May; 52(9):2880-98. PubMed ID: 19348494
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
